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aBstraCt
introduCtion. Ranibizumab is an anti-VEGF antibody widely used in DME treatment.
MateriaLs and Methods. We conducted a literature search using the keywords “diabetes”, “diabetic retinopathy”, 
“diabetic macular edema”, “pathophysiology”, “VEGF”, “treatment”, “anti-VEGF”, “ranibizumab”, “lucentis” with 
limitation of English language. The articles published between 2006–2016 years and we reviewed level I and level 
II studies.
resuLts. Review from several level I and level II intravitreal ranibizumab injection studies suggests that ranibizum-
ab is an anti-VEGF that effectively used in DME treatment. Comparison with other anti-VEGF also suggest that 
ranibizumab is effective for DME patients for over 2 years treatment.
ConCLusions. Ranibizumab monotherapy and/or combination with laser is safe and effective for DME patients 
for over 2 years treatment.
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introduCtion
Diabetes is considered as chronic disease and di-
agnosed by observing the increase of blood glucose 
level.1 High blood glucose can lead to different 
organ damage including the eyes.[1, 2] 
Many aged 20–74 years diabetes develop some 
form of eye disease (Diabetic Retinopathy), with 
potential loss of vision [1–4].
Based on 2012 study, 35% people with diabetes 
had some form of Diabetic Retinopathy and 7% 
had Proliferative Diabetic Retinopathy, 7% had Di-
abetic Macular Edema, and 10% were affected by 
vision-threatening stages [5]. 
Diabetic Macular Edema (DME) is a common 
complication of diabetic retinopathy which is char-
acterized by a swelling of the macular area due to 
leakage of proteins through vascular walls following 
the development of intracellular as well as extra-
cellular hypertonic environments after an ischemic 
event [6, 7]. 
Vascular Endothelial Growth Factor (VEGF) is 
a major mediator of blood retinal barrier (BRB) 
breakdown and the development of macular ede-
ma.6 VEGF is a disulfide-bound homodimer glyco-
protein. It is one of the most important regulators 
of vasculogenesis and angiogenesis. An inflamma-
tion-induced breakdown of the BRB is mediated by 
VEGF via binding to leukocytes and inducing their 
recruitment to the site of the inflammation. There 
are 5 types of VEGF which are VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and VEGF-E. The VEGF that 
is involved in the development of macular edema in 
the eyes is mainly VEGF-A [7].
Therefore, currently, anti-VEGF treatment is 
one of the promising treatment of visual loss in 
DME patients [6, 8].
Arief Kartasasmita et al., Ranibizumab in Diabetic Macular Edema
15www.journals.viamedica.pl/ophthalmology_journal
MateriaLs and Methods
We conducted a literature search on PubMed®, 
Google Scholar™, and Cochrane® databases using 
the keywords “diabetes”, “diabetic retinopathy”, 
“diabetic macular edema”, “pathophysiology”, 
“VEGF”, “treatment”, “anti-VEGF”, “ranibizum-
ab”, “lucentis” with limitation of English language. 
The articles published between 2006–2016 years 
and we reviewed level I and level II studies.
Definition of level I studies are “high quality 
randomized trial or prospective study; testing of 
previously developed diagnostic criteria on consec-
utive patients; sensible costs and alternatives; values 
obtained from many studies with multiway sensitiv-
ity analyses; systematic review of Level I (RCT) and 
Level I studies” [9].
Level II studies are “less quality RCT; prospec-
tive comparative study; retrospective study; untreat-
ed controls from an RCT; less quality prospective 
study; development of diagnostic criteria on consec-
utive patients; sensible costs and alternatives; values 
obtained from limited studies; with multiway sensi-
tivity analyses; systematic review of Level II studies 
or Level I studies with inconsistent results” [9].
resuLts 
Two anti-VEGF is approved for the DME treat-
ment, ranibizumab (Lucentis®; Genentech Inc., San 
Francisco, Calif., USA) and aflibercept (EYLEA®; 
Regeneron, Tarrytown, N.Y., USA). Bevacizumab 
currently is not approved for diabetic macular ede-
ma but widely used as “off label”. 
Ranibizumab is a humanized monoclonal anti-
body that binds all biologically active isoforms and 
active proteolytic fragments of VEGF-A, therefore 
preventing VEGF-A to bind with its receptor. [10]
A pilot study of ranibizumab injection in 10 pa-
tients showed that ranibizumab is well tolerated, has 
potential to maintain or improve BCVA and reduce 
retinal thickness in patients with center-involved 
clinically significant DME [11]. 
Several level I studies such as Diabetic Retin-
opathy Clinical Network (DRCR.net), RESTORE 
Study, RISE and RIDE support the use of ranibi-
zumab for DME patients. These studies reported 
that ranibizumab monotherapy or combination 
with laser give a better visual acuity outcomes at 
1 to 2 years compared with laser or triamcinolone 
[12–15]. When comparing with other anti-VEGF 
(bevacizumab and aflibercept), one study (Protocol 
T) showed that in year 1 among eyes with worse 
baseline VA, aflibercept showed superiority over ra-
nibizumab and bevacizumab but at year 2, the su-
periority over ranibizumab was no longer identified 
(Table 1) [16, 17].
In The Diabetic Retinopathy Clinical Research 
Network (DRCR.net) evaluation of intravitreal 
0.5 mg ranibizumab or 4 mg triamcinolone com-
bined with focal/grid laser compared with focal/grid 
laser monotherapy for treatment of diabetic macular 
edema were studied.
A total 854 study eyes were randomized of com-
bination sham injection and prompt laser (n = 293), 
0.5 mg ranibizumab and prompt laser (n = 187), 
0.5 mg ranibizumab and deferred laser (n = 188), 
or 4 mg triamcinolone and prompt laser (n = 186). 
Prompt laser was given 3–10 days after injection 
while deferred laser was given ≥ 24 weeks, intravit-
real study drug or sham injection retreatments every 
4 weeks based on criteria in the protocol [12].
The 1-year mean change in the visual acuity 
letter score from baseline was significantly greater in 
the combination of ranibizumab and prompt laser 
group and ranibizumab and deferred laser group 
(both +9 letters and p < 0.05) but not in the com-
bination of triamcinolone and prompt laser group 
(+4 letters, p = 0.31) compared with prompt laser 
monotherapy group (+3 letters). Conclusion of the 
2-year expanded results are similar with to 1-year re-
sults that combination of ranibizumab with prompt 
or deferred laser is more effective compared with 
prompt laser monotherapy [12, 13].
The study extended to 5-year and from 3-year 
follow up, the objective is to evaluate prompt versus 
deferred (for ≥ 24 weeks) focal/grid laser treatment 
in eyes treated with intravitreal 0.5 mg ranibizum-
ab. Five-year result suggest that focal/grid laser treat-
ment at the initiation of ranibizumab is no better 
than deferred laser [18, 19]. 
Another level I, RESTORE Study, a multicenter, 
randomized, double-masked, laser-controlled 
phase III study. Three hundred forty five DME 
patients randomized into 3 groups, 0.5 mg ranibi-
zumab + sham laser (n = 116), 0.5 mg ranibizum-
ab + active laser (n = 118), or laser + sham injection 
(n = 111). Ranibizumab/sham injection was given 
3 months then pro re nata (PRN); laser/sham laser 
was given at baseline then PRN [14]. 
In the 12 month report, ranibizumab monother-
apy and combination with laser were superior to la-
ser alone in improving mean change in BCVA from 
baseline to month 1 through month 12 (+6.1 and 
+5.9 vs. +0.8; both p < 0.0001). The mean cen-
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tral retinal thickness was significantly reduced 
from baseline with ranibizumab monotherapy 
(-118.7 µm) and ranibizumab + laser combination 
(-128.3 µm) versus laser monotherapy (-61.3 µm; 
both p < 0.001) [14]. 
All patients eligible to receive 0.5 mg ranibi-
zumab PRN from month 12 in RESTORE study 
included in extension study. Overall, 208 patients 
completed the extension study. Individualized ra-
nibizumab treatment during the extension study 
could maintain the BCVA and central retinal thick-
ness (CRT) observed at month 12 over the 2-year 
extension study (+8.0 letters, -142.1 µm [prior 
ranibizumab] and +6.7 letters, -145.9 µm [prior 
ranibizumab + laser] from baseline at month 36). 
Mean injection of 6.8 injections in prior ranibi-
zumab group and 6.0 injections in prior ranibi-
zumab + laser group. No new safety concern in 
ranibizumab group were identified [20, 21].
Two parallel, methodologically identical, 
phase III, multicenter, double-masked, sham in-
jection–controlled, randomized studies, RISE and 
RIDE. Ranibizumab was given monthly and in the 
third year, eligible patients sham patients cross-over 
to 0.5 mg ranibizumab while still masked [15].
In RISE, 377 patients were randomized (sham 
n = 127, 0.3 mg ranibizumab n = 125, 0.5 mg 
ranibizumab n = 125).17,18 At 24 months, 18.1% 
of sham patients gained ≥ 3 lines versus 44.8% of 
0.3 mg and 39.2% of 0.5 mg ranibizumab patients 
( both p < 0.05) [15]. 
Visual acuity (VA) outcomes in ranibizumab 
group were consistent from month 24 through 
through month 36. Proportions of patients who 
gained ≥ 3 lines from baseline at month 36 in the 
sham/0.5 mg, 0.3 mg, and 0.5 mg ranibizumab 
groups were 22.0%, 51.2%, and 41.6%, respective-
ly [22].
In RIDE, 382 patients were randomized 
(sham n = 130, 0.3 mg n = 125, 0.5 mg 
n = 127). At 24 months, ranibizumab-treated pa-
tients gained ≥ 3 lines: 12.3% of sham patients ver-
sus 33.6% of 0.3-mg and 45.7% of 0.5-mg ranibi-
zumab (both p < 0.0001) [15]. 
Visual acuity (VA) outcomes in ranibizumab 
group were consistent at month 24 through month 
36. Proportions of patients who gained ≥ 3 lines 
from baseline at month 36 in the sham/0.5 mg, 
0.3 mg, and 0.5 mg ranibizumab groups were 
19.2%, 36.8%, and 40.2%, respectively [22].
A “head to head” study, multicenter trial com-
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aflibercept in United States. Six hundred and sixty 
adults with DME was randomized to receive in-
travitreal injection 2.0 mg aflibercept (n = 224), 
1.25 mg bevacizumab (n = 218), or 0.3 ranibi-
zumab (n = 218) every 4 weeks based on criteria 
in the protocol. If DME persisted after 6 months, 
focal/grid laser photocoagulation could be added 
[16, 17].
Improvement in mean VA from baseline to 
1 year were 13.3 letters with aflibercept, 9.7 letters 
with bevacizumab, and 11.2 letters with ranibi-
zumab. The difference in the improvement between 
3 anti-VEGF was not clinically meaningful because 
it was driven by the eyes with worse visual acuity at 
baseline (p < 0.001 for interaction) [16]. 
When the baseline of visual acuity was 78 to 
69 letters (equivalent to approximately 20/32 to 
20/40) (51% participants), the mean improvement 
was 8.0 letters with aflibercept, 7.5 letters with 
bevacizumab, and 8.3 letters with ranibizumab 
(p > 0.50 for each pairwise comparison).
There were no significant differences among 
the study groups in the rates of serious adverse 
events [16].
In 2-year, median number of injection for af-
libercept, bevacizumab, and ranibizumab were 5, 
6, and 6, respectively. While the median number 
over 2 years were 15, 16, and 15 in the aflibercept, 
bevacizumab, and ranibizumab groups, respectively. 
Forty one percent in aflibercept groups, 64% in bev-
acizumab group, and 52% in ranibizumab groups 
was administered focal/grid laser photocoagulation 
(aflibercept vs either ranibizumab or bevacizumab 
and bevacizumab vs ranibizumab all p < 0.05) [17].
Mean VA improvement at 2 years were 12.8, 
10.0, and 12.3 letters in aflibercept, bevacizumab, 
and ranibizumab respectively. The study concluded 
not only aflibercept, bevacizumab, and ranibizumab 
showed VA improvement from baseline to 2 years 
but also a decreased number of injections in year 
2. Aflibercept had superior VA outcome compared 
with bevacizumab in 2-year but the superiority 
compared with ranibizumab that is shown in year 
1 is no longer shown in year 2 [17].
The regimen used in the “head to head” trials is 
not reflected the clinical practice in Indonesia where 
ranibizumab available and approved by Indonesian 
health authority is 0.5 mg. 
RESOLVE and READ-2 studies are 2 level II 
studies reported ranibizumab monotherapy or com-
bination improved BCVA until 1 to 2 years com-
pared with no treatment or with laser [23-25]. One 
Arief Kartasasmita et al., Ranibizumab in Diabetic Macular Edema
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level II study, READ-2, showed the mean decrease 
of CRT is significant compared sham patients. [25]
READ-2 conducted in multicenter, 126 DME 
patients randomized into three groups. Group 1 re-
ceive 0.5 ranibizumab at baseline, month 1, month 
3, and month 5 (n = 42); group 2 received focal/grid 
laser photocoagulation at baseline and month 3 pro 
re nata (n = 42), or group 3 is combination of 
0.5 mg ranibizumab and focal/grid laser at baseline 
and month 3 (n = 42) [12, 13]. 
The primary endpoint month 6, the mean 
change of BCVA was significantly greater in group 
1 compared with group 2 (+7.2 vs. -0.43 letters, 
p = 0.01), and group 3 (+3.8 letters) was not statis-
tically different from the other 2 groups. Improve-
ment of ≥ 3 lines occurred in 22% group 1, 0% in 
group 2 (p = 0.002), and 8% in group 3 [24].
After 6 months, most patients were continued 
with ranibizumab, 33 patients in group 1, 34 pa-
tients in group 2, and 34 patients in group 3 re-
mained in the study through 24 months, with mean 
improvement in BCVA 7.7, 5.1, and 6.8 letters at 
month 24. Patients who gained ≥ 3 lines was 24%, 
18%, and 26% at month 24 [24]. 
In RESOLVE study, phase II clinical tri-
al, 151 patients was randomized to ranibizumab 
0.3 mg (n = 51), ranibizumab 0.5 mg (n = 51), or 
sham treatment (n = 49) three monthly injection. 
Thereafter, treatment could be stopped or reiniti-
ated with an opportunity for rescue laser photoco-
agulation (based on protocol). After month 1, the 
ranibizumab dosage (or sham) could be doubled to 
0.6 mg (for ranibizumab 0.3 mg) and 1.0 mg (for 
ranibizumab 0.5 mg) if met indicated by specific 
study criteria. 
At month 12, BCVA improvement from base-
line were +10.3 letters in ranibizumab group and 
decline in sham group by -1.4 letters (p < 0.0001). 
Mean CRT reduction is -194.2 µm with ranibizum-
ab and -48.4 µm with sham (p < 0.0001). In ranibi-
zumab group, 60.8% gain ≥ 10 letters from baseline 
and 18.4% in sham group (p < 0.0001) [25].
ConCLusions
Review from several level I and level II intra-
vitreal ranibizumab injection studies suggests that 
ranibizumab alone and/or combination with laser is 
safe and effective for DME patients for over 2 years 
treatment. 
Comparison with other anti-VEGF also suggest 
that ranibizumab is effective for DME patients for 
over 2 years treatment. Future research on the safety 
and effective ranibizumab o.5 mg compared with 
other anti-VEGF is required.
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